<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-PRNRC-09000307</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2009-01-12</date_registration>
      <primary_sponsor>Peking University People's Hospital</primary_sponsor>
      <public_title>Preemptive therapy guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia</public_title>
      <acronym />
      <scientific_title>Preemptive therapy guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2004-11-01</date_enrolment>
      <type_enrolment />
      <target_size>Low-risk group:56;High-risk group:28;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=9223</url>
      <study_type>Prognosis study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>Other</phase>
      <hc_freetext>chronic myeloid leukemia</hc_freetext>
      <i_freetext>Low-risk group:Protocol 1: Immunosuppressant withdrawal. Protocol 2: Imatinib therapy. Protocol 3: Modified donor lymphocyte infusion;High-risk group:Protocol 1: Immunosuppressant withdrawal. Protocol 2: Imatinib therapy. Protocol 3: Modified donor lymphocyte infusion.;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Chang Yingjun</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen South, Xicheng District, Beijing</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 010 88324671</telephone>
        <email>changyingjun3621@tom.com</email>
        <affiliation>Peking University People's Hospital &amp; Peking University Institute of Hematology</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Huang Xiaojun</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen South Street, Xicheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 010 88324984</telephone>
        <email>xjhrm@medmail.com.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with chronic myeloid leukemia who are candidates of allogeneic hematopoiectic stem cell transplantation, consent forms were signed</inclusion_criteria>
      <agemin>12</agemin>
      <agemax>51</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with chronic myeloid leukemia who have no suitable donors or whose economic situation is poor</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>graft-versus-host disease;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Overall survival and leukemia-free survival,relapse, and treatment-related mortality;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>HI-Tech Research Development Program of China 863 (grant no.2006AA02Z4A0)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>